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ABSTRACT
Invasive micropapillary carcinoma (IMPC) of the breast is a highly aggressive breast
cancer. Polarity reversal exemplified by cluster growth is hypothesized to contribute to
the invasiveness and metastasis of IMPC. In this study, we demonstrate that levels of
β1 integrin and Rac1 expression were greater in breast IMPC than in invasive breast
carcinoma of no specific type and paraneoplastic benign breast tissue. We show that
silencing β1 integrin expression using the β1 integrin inhibitor AIIB2 partially restored
polarity in IMPC primary cell clusters and downregulated Rac1. Thus, overexpression
of β1 integrin upregulates Rac1. Univariate analysis showed that overexpression of β1
integrin and Rac1 was associated with breast cancer cell polarity reversal, lymph node
metastasis, and poor disease-free survival in IMPC patients. Multivariate analysis revealed
that polarity reversal was an independent predictor of poor disease-free survival. These
findings indicate that overexpression of β1 integrin and the resultant upregulation of Rac1
contribute to polarity reversal and metastasis of breast IMPC, and that β1 integrin and
Rac1 could be potential prognostic biomarkers and targets for treatment of breast IMPC.

INTRODUCTION

IMPC exhibits polarity reversal in cell clusters, which
increases the risk of invasion and metastasis [6]. Polarity
reversal can be identified by immunohistochemistry
(IHC) for E-cadherin (E-cad), epithelial membrane
antigen (EMA), mucin family protein-1 (MUC-1), and
sialyl-Lewis X (SleX) [7–10]. Liu et al. [11] reported
that presence of IMPC in breast mucinous carcinoma
promotes tumor metastasis and that patients with mixed

Invasive micropapillary carcinoma (IMPC) is a
tumor with a propensity for metastasis that occurs in
various organs [1–3]. It was first reported in the breast by
Fisher et al. [4] in 1980, and the term was adopted by the
World Health Organization (WHO) classification of breast
tumors in 2003 [5]. We have previously shown that breast
www.impactjournals.com/oncotarget
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IMPC/mucinous carcinoma have worse recurrence-free
survival and overall survival (OS) than patients with
pure mucinous carcinoma. We theorized that polarity
reversal of tumor cell clusters contributes to invasion and
metastasis of IMPC and thus to its poor prognosis [12].
Integrins are a family of transmembrane receptors.
They are heterodimers composed of α and β subunits.
β1 integrin is mainly expressed in normal cells. Lee et
al. [13] found that β1 integrin helps maintain polarity
of normal epithelial cells and assists in the formation of
glandular lumen. Aberrant expression of β1 integrin in
human breast carcinoma has been linked to cell adhesion,
angiogenesis, tumor progression, and metastasis [14,
15]. Overexpression of β1 integrin has been reported
in several solid tumors [14, 16], and inhibition of β1
integrin expression in breast cancer cell lines restores
the polarity of tumor cells to a status similar to normal
mammary epithelial cells [17, 18]. Other studies showed
that treatment of normal epithelial MDCK cells with
β1 integrin inhibitor resulted in polarity disorder and
malignant phenotype transformation [19, 20]. Thus,
balanced expression of β1 integrin is required to maintain
normal polarity.
Rac is a member of the Rho family of small
GTPases that is regulated by integrin and affects a
variety of actin-dependent processes including cell-cell
adhesion, cell migration, and cellular transformation [21].
Studies have demonstrated that Rac1 induces epithelial
polarity in cells adhering to extracellular matrix [22] and
contributes to cell migration, loss of adhesion, invasion,
and metastasis of tumors [23]. However, its expression and
regulatory relationship with β1 integrin in IMPC have not
been reported.
Here, we examined β1 integrin and Rac1 expression
and assessed their effects on polarity at the cytologic level.
We then validated our results in breast cancer cell lines
and primary breast cancer cells. We further correlated our
findings with patients’ clinical outcomes.

β1 integrin silencing leads to disordered polarity
of MCF-10A cell clusters

RESULTS

To assess whether β1 integrin induces polarity
changes, we planted IMPC primary tumor cells in collagen
gel for 3D culture and then treated the cells with AIIB2.
Rhodamine-conjugated affinipure goat anti-rabbit IgG was
used to label MUC-1 (red), and rhodamine-conjugated
affinipure goat anti-mouse IgG was used to label E-cad
(green). Immunofluorescence analysis identified polarity
reversal in IMPC cell clusters without AIIB2 treatment.
After AIIB2 treatment, polarity was partially restored.
Similar changes were observed in IDC-NST cells
(Figure 3). These observations suggest that β1 integrin
overexpression causes tumor cell polarity reversal.

To assess polarity changes induced by β1 integrin,
we planted MCF-10A cells in collagen gel for threedimensional (3D) culture and then silenced β1 integrin
expression using siRNA. MUC-1, the marker of cell
polarity, was detected by rhodamine-conjugated affinipure
goat anti-rabbit IgG (red). Immunofluorescence analysis
of the siRNA-ctrl control group showed that MUC-1 was
expressed on the inner side of the cell clusters, indicating
that MCF-10A cell clusters displayed normal polarity. As
shown in Figure 1E, after treatment with siRNA-β1 integrin,
MUC-1 staining was predominantly located on the stromafacing surface of the cell clusters, demonstrating polarity
reversal. The cell clusters were transformed from having a
hollow growth pattern to irregular clusters. When cells were
treated with siRNA-Rac1, cell cluster polarity also became
disordered (Figure 1E). These observations indicate that
loss of β1 integrin and/or Rac1 can lead to disordered cell
polarity in 3D culture.

AIIB2 downregulates Rac1 in breast cancer cell
lines and IMPC primary tumor cells
In 3D cell culture, we treated MCF-7 and MDAMB-231 breast cancer cell lines, as well as primary tumor
cells of IMPC and invasive ductal carcinoma of no specific
type (IDC-NST), with AIIB2, a β1 integrin inhibitor used in
previous studies [24–26]. After 72 hours of incubation with
AIIB2, Rac1 protein levels decreased in both cancer cell
lines (Figure 2A) and primary tumor cells (Figure 2B, 2C),
indicating that AIIB2-induced inhibition of β1 integrin
downregulates Rac1. These findings support the earlier
conclusion that β1 integrin positively regulates Rac1
expression.

AIIB2 causes polarity change in IMPC cell
clusters

β1 integrin positively regulates Rac1 expression
We first evaluated the silencing effects of siRNA-β1
integrin and siRNA-Rac1 in MCF-10A normal breast
epithelial cells. siRNA-ctrl was used as negative control.
As shown in Figure 1A and 1B, β1 integrin mRNA
was significantly decreased with siRNA-β1 integrin
transfection. Rac1 mRNA was also significantly decreased
with siRNA-Rac1 transfection. At the protein level,
both β1 integrin expression and Rac1 expression were
decreased (Figure 1C). When cells were transfected with
siRNA-Rac1, Rac1 expression was downregulated, but no
significant decrease in β1 integrin expression was noted
(Figure 1D). The results indicate that Rac1 expression is
positively regulated by β1 integrin.
www.impactjournals.com/oncotarget

β1 integrin and Rac1 are overexpressed in IMPC
We evaluated β1 integrin and Rac1 expression in
breast IMPC tissues by IHC. β1 integrin was mainly
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expressed on the cell membrane with brown-yellow color
(Figure 4A). Rac1 was predominantly expressed in the
nucleus, whereas the cytoplasm was stained with brown
particles (Figure 4A). Of 102 IMPC samples, 80 (78.4%)
demonstrated high β1 integrin levels and 81 (79.4%)
demonstrated high Rac1 levels. Of 48 paraneoplastic

benign breast tissue samples, 30 (62.5%) demonstrated
high β1 integrin levels and 29 (60.4%) demonstrated
high Rac1 levels. β1 integrin and Rac1 levels were
significantly greater in IMPC than paraneoplastic benign
breast tissue (P = 0.040 and P = 0.035, respectively)
(Table 1).

Figure 1: β1 integrin and Rac1 expression and polarity of breast cancer cell lines with silencing of β1 integrin and
Rac1. (A, B) β1 integrin and Rac1 mRNA in MCF-10A was downregulated after transfection with siRNA-β1 integrin and siRNA-Rac1.

(C, D) Decreased β1 integrin and Rac1 protein expression in MCF-10A was detected by Western blot after transfection with siRNA-β1
integrin and siRNA-Rac1. β-actin was used as control. (E) Disordered polarity of MCF-10A cell clusters in 3D culture after treatment with
siRNA-β1 integrin and siRNA-Rac1 is shown. Normal polarity was determined by MUC-1 (red) at the luminal surface of control cells.
Nuclei are shown with DAPI (blue). Scale bars, 50 µm. si-ctrl: control cell line.
www.impactjournals.com/oncotarget
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expression (87.7% vs 61.9%; P = 0.006). Similarly, IDCNST patients with high β1 integrin expression had a higher
incidence of LNM than patients with low expression
(61.9% vs 37.8%; P = 0.020) (Table 3). Overexpression
of β1 integrin in IMPC was positively correlated with
LNM (rs = 0.273, P = 0.005), Rac1 expression (rs = 0.280,
P = 0.004), and polarity reversal (rs = 0.268, P = 0.007).
However, no significant association was observed between
β1 integrin expression and age, tumor size, histologic
grade, or estrogen receptor (ER), progesterone receptor
(PR), or human epidermal growth factor receptor 2
(HER2) status (Table 4).

Of 100 IDC-NST samples, 63 (63%) demonstrated
high β1 integrin levels and 67 demonstrated high Rac1
levels. β1 integrin and Rac1 levels were significantly
greater in IMPC than IDC-NST (Z = –2.571, P = 0.010;
and Z = –1.988, P = 0.047 respectively) (Table 2).

Upregulated β1 integrin expression correlates
with lymph node metastasis (LNM), polarity
reversal, and Rac1 overexpression in IMPC
IMPC patients with high β1 integrin expression
had a higher incidence of LNM than patients with low

Figure 2: Expression of β1 integrin and Rac1 in breast cancer cell lines and primary tumor cells at 3D culture treated
with β1 integrin inhibitor AIIB2 and detected by Western blot. (A) Rac1 expression in MCF-7 and MDA-MB-231 was lower

than in controls. (B, C) Rac1 expression in IMPC and IDC-NST tumor cells was decreased. β-Actin was used as control. Relative gray
value was defined as the ratio between the gray value of Rac1 and β-actin (student’s t-test, *P < 0.05). T1-T3: 3 cases of IMPC primary
tumor; T4-T6: 3 cases of IDC-NST primary tumor.
www.impactjournals.com/oncotarget
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Upregulated Rac1 expression correlates with
LNM and polarity reversal in IMPC

(Table 6). Thirty-seven IDC-NSTs showed low β1 integrin
expression: 21 had weak expression and 16 had negative
expression. Eleven (52.4%) of 21 IDC-NST patients
with weak β1 integrin expression had LNM, whereas 3
(18.8%) of 16 patients with negative expression had LNM
(P = 0.037) (Table 6).
Twenty-one IMPCs showed low Rac1 expression:
13 had weak expression and 8 had negative expression.
Ten (76.9%) of 13 IMPC patients with weak Rac1
expression had LNM, whereas 2 (25%) of 8 patients
with negative expression had LNM (P = 0.020) (Table
6). Thirty-three IDC-NSTs showed low Rac1 expression:
14 had weak expression and 19 had negative expression.
Eight (57.1%) of 14 IDC-NST patients with weak Rac1
expression had LNM, whereas 4 (21.1%) of 19 patients
with negative expression had LNM (P = 0.033) (Table 6).

IMPC patients with high Rac1 expression had
a higher incidence of LNM than patients with low
expression (88.9% vs 57.1%; P = 0.001). Similarly, IDCNST patients with high Rac1 expression had a higher
incidence of LNM than patients with low expression
(61.2% vs 36.3%; P = 0.019) (Table 3). Overexpression
of Rac1 in IMPC was positively correlated with LNM
(rs = 0.337, P = 0.001), β1 integrin expression (rs = 0.280,
P = 0.004), and polarity reversal (rs = 0.268, P = 0.007).
No significant associations were observed between Rac1
expression and age, tumor size, histologic grade, or ER,
PR, or HER2 status (Table 5).
LNM rate is significantly higher for IMPC and IDCNST tumors with weak β1 integrin and Rac1 expression
than in tumors with negative expression
Twenty-one IMPCs showed low β1 integrin
expression: 14 had weak expression and 7 had negative
expression. Eleven (78.6%) of 14 IMPC patients with weak
β1 integrin expression had LNM, whereas 2 (28.6%) of 7
patients with negative expression had LNM (P = 0.026)

Polarity reversal correlates with LNM and β1
integrin expression in IMPC patients
Among the 102 IMPC patients, 84 (82.4%)
demonstrated LNM, an incidence significantly higher than
that in IDC-NST patients (53%; P = 0.000) (Table 2). No

Figure 3: Polarity alterations induced by the β1 integrin inhibitor AIIB2. IMPC and IDC-NST cells were stained with anti-

MUC-1 antibody (red) and anti-E-cadherin antibody (green), and the nuclei were stained with DAPI (blue). Representative confocal
images were taken. Scale bars, 50 µm.
www.impactjournals.com/oncotarget
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Our results indicate that polarity reversal is associated
with increased LNM in IMPC.

significant differences in patient age, tumor size, histologic
grade, or ER, PR, or HER2 status were identified between
the IMPC and IDC-NST groups (P > 0.05) (Table 2).
We next investigated the association between
polarity reversal (Figure 4B, 4C) and β1 integrin
expression, Rac1 expression, and LNM rate in vivo by
MUC-1 IHC. Among the 102 IMPC samples, 87 (85.3%)
showed reversed polarity; in contrast, 4 (4%) of 100
IDC-NST samples showed reversed polarity (Table 2).
Polarity reversal in IMPC was positively correlated with
overexpression of β1 integrin (rs = 0.268, P = 0.007) and
Rac1 (rs = 0.268, P = 0.007) and presence of LNM (rs =
0.316, P = 0.001). No significant association was observed
between polarity reversal and age, tumor size, histologic
grade, or ER, PR, or HER2 status (P > 0.05) (Table 7).

Overexpression of β1 integrin correlates with
poor prognosis of IMPC patients
To assess whether β1 integrin expression correlates
with the prognosis of IMPC patients, DFS and OS analyses
were performed in all patients. Kaplan-Meier survival curves
showed that DFS was significantly shorter in patients with
overexpression of β1 integrin or Rac1 or with polarity
reversal than in patients with low β1 integrin or Rac1
expression or without polarity reversal (P = 0.017, P = 0.026,
and P = 0.003, respectively) (Figure 5A–5C). The DFS of
patients with both β1 integrin and Rac1 overexpression was

Figure 4: (A) Immunohistochemical stain of β1 integrin and Rac1 in IMPC and IDC-NST (×200). β1 integrin was

predominantly expressed on the cell membrane with brown-yellow color, whereas Rac1 was primarily expressed in the nucleus and
cytoplasm. (B) Reversed immunohistochemistry pattern of MUC-1 in IMPC, which was defined as the presence of complete linear
reactivity on the outer surface of tumor cell clusters facing stroma (×200). (C) Nonreversed immunohistochemistry pattern of MUC-1 in
IMPC, which was defined as whole cytoplasmic membrane staining of tumor cell clusters (×200).
www.impactjournals.com/oncotarget
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Table 1: β1 integrin and Rac1 expression in IMPC and paraneoplastic benign breast tissue
Protein expression
β1 integrin
High
Low
Rac1
High
Low

Paraneoplastic
benign breast n (%)

IMPC
n (%)

χ2

P value*

30 (62.5)
18 (37.5)

80 (78.4)
22 (21.6)

4.236

0.040

29 (60.4)
17 (35.4)

81 (79.4)
21 (20.6)

4.451

0.035

IMPC:invasive micropapillary carcinoma.
*
P values were calculated by χ2 test.
Table 2: Clinicopathological characteristics of IMPC and IDC-NST patients
IMPC(%)

IDC-NST(%)

Z

P value*

43 (42.2)
59 (57.8)

55 (55)
45 (45)

−1.882

0.069

28 (27.5)
60 (58.8)
14 (13.7)

36 (36)
57 (57)
7 (7)

−1.712

0.087

10 (9.8)
67 (65.7)
25 (24.5)

13 (13)
71 (71)
16 (16)

−1.512

0.131

18 (17.6)
84 (82.4)

47 (47)
53 (53)

−4.454

0.000

43 (42.2)
59 (57.8)

41 (41)
59 (59)

−0.166

0.868

41 (40.2)
61 (59.8)

39 (39)
61 (61)

−0.173

0.862

83 (81.4)
19 (18.6)

71 (71)
29 (29)

−1.727

0.084

21 (20.6)
81 (79.4)

37 (37)
63 (63)

−2.571

0.010

21 (20.6)
81 (79.4)

33 (33)
67 (67)

−1.988

0.047

Non-reversed pattern

15 (14.7)

96 (96)

Reversed pattern

87 (85.3)

4 (4)

−11.582

0.000

Characteristics
Age (years)
≤52
﹥52
Tumor size (T stage)
T1
T2
T3–T4
Histological grade
I
II
III
Lymph node status
No metastasis
metastasis
ER status
Negative
Positive
PR status
Negative
Positive
Her2 status
Negative
Positive
β1 integrin expression
Low
High
Rac1 expression
Low
High
MUC-1 expression

ER:estrogen receptor, PR:progesterone receptor, HER-2:human epidermal growth factor receptor 2, IMPC:invasive micropapillary
carcinoma, IDC-NST: invasive breast carcinoma of no specific type.
*
P values were calculated by Mann-Whitney U test.
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Table 3: Lymph node metastasis of IMPC and IDC-NST with low or high expression of β1 integrin and Rac1
Histologycal
type

β1 integrin
expression
high
low

LN status

2

χ

P*
value

7.608

0.006

5.420

0.020

Rac1
expression
high
low

χ2

P*
value

11.565

0.001

5.472

0.019

IMPC
Metastasis

71

13

No metastasis

10

8

Metastasis

39

14

No metastasis

24

23

71

12

9

9

41

12

26

21

IDC-NST

IMPC:invasive micropapillary carcinoma, IDC-NST: invasive breast carcinoma of no specific type, LN: Lymph node
*
P values were calculated by χ2 test.
Table 4: β1 integrin expression and clinicopathological characteristics of IMPC patients
Characteristics

β1 integrin expression
Low

High

rs

P value*

-0.140

0.160

-0.014

0.889

0.095

0.343

0.273

0.005

–0.189

0.057

-0.170

0.087

0.057

0.571

0.280

0.004

0.268

0.007

Age(years)
≤52
﹥52
Tumor size (T stage)
T1
T2
T3–T4

6

37

15

44

3
18

25
42

0

14

Histological grade
I

2

8

II

16

51

III
Lymph node status

3

22

No metastasis

8

10

metastasis

13

71

5

38

16

43

Negative

5

36

Positive

16

45

Negative

18

65

Positive

3

16

Low

9

12

High

12

69

Non-reversed pattern

7

8

Reversed pattern

14

73

ER status
Negative
Positive
PR status

Her2 status

Rac1 expression

MUC-1 expression

ER:estrogen receptor, PR:progesterone receptor, HER-2:human epidermal growth factor.
receptor 2, IMPC:invasive micropapillary carcinoma.
*
P values were calculated by Spearman’s Rank-Correlation test.
www.impactjournals.com/oncotarget
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Table 5: Rac1 expression and clinicopathological characteristics of IMPC patients
Characteristics
Age(years)
≤52
﹥52
Tumor size (T stage)
T1
T2
T3-T4
Histological grade
I
II
III
Lymph node status
No metastasis
metastasis
ER status
Negative
Positive
PR status
Negative
Positive
Her2 status
Negative
Positive
β1 integrin expression
Low
High
MUC-1 expression
Non-reversed pattern
Reversed pattern

Rac1 expression

rs

P value*

34
47

0.007

0.943

5
14
2

23
46
12

–0.001

0.993

3
13

7
54

0.042

0.673

5

20

9
12

9
72

0.337

0.001

9
12

34
47

0.007

0.943

5
16

36
45

–0.170

0.087

16
5

67
14

–0.068

0.499

9
12

12
69

0.280

0.004

7
14

8
73

0.268

0.007

Low

High

9
12

ER:estrogen receptor, PR:progesterone receptor, HER-2:human epidermal growth factor.
receptor 2, IMPC:invasive micropapillary carcinoma.
*
P values were calculated by Spearman’s Rank-Correlation test.
significantly shorter than in patients with overexpression of
only β1 integrin or Rac1 (P = 0.029 and P = 0.019 separately),
whereas no significant difference in DFS was noted between
patients with overexpression of both β1 integrin and Rac1 and
patients with low expression of both of these markers (Figure
5D). No significant OS differences were observed between
patients with and without high expression of β1 integrin and/
or Rac1 or patients with and without polarity reversal (data
not shown). Univariate Cox regression analysis revealed that
increased tumor size, presence of LNM, overexpression of
β1 integrin and/or Rac1, and polarity reversal are associated
www.impactjournals.com/oncotarget

with worse DFS in patients with IMPC (P < 0.05) (Table
8). However, multivariate Cox regression analysis only
confirmed that increased tumor size (P = 0.010) and polarity
reversal (P = 0.031) were independent predictors of poor
DFS in IMPC patients (Table 8).

DISCUSSION
Pure breast IMPC is rare, constituting <2% of breast
cancers; however, IMPC has a high rate of metastasis.
Currently, there are no universally accepted criteria for
4346
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Table 6: Lymph node metastasis in IMPC and IDC-NST with β1 integrin and Rac1 low expression
Pathology type

LN status

IMPC
IDC-NST

β1 integrin expression
+

–

LN+

11

2

LN-

3

5

LN+

11

3

LN-

10

13

χ2

P value*

4.947

0.026

4.367

0.037

Rac 1 expression
+

–

10

2

3

6

8

4

6

15

χ2

P value*

5.452

0.020

4.537

0.033

IMPC:invasive micropapillary carcinoma, IDC-NST: invasive breast carcinoma of no specific type.
*
P values were calculated by χ2 test.
Table 7: MUC-1 expression and clinicopathological parameters of IMPC patients
Characteristics

MUC-1 expression
Non-reversed pattern

Reversed pattern

≤52

4

39

﹥52

11

48

T1

4

24

T2

9

51

T3–T4

2

12

I

3

7

II

9

58

III

3

22

No metastasis

7

11

metastasis

8

76

Negative

5

38

Positive

10

49

Negative

3

38

Positive

12

49

Negative

12

71

Positive

3

16

Low

7

14

High

8

73

Low

7

14

High

8

73

rs

P value*

–0.130

0.192

–0.003

0.974

0.101

0.312

0.316

0.001

–0.074

0.459

–0.171

0.086

0.015

0.884

0.268

0.007

0.268

0.007

Age (years)

Tumor size (T stage)

Histological grade

Lymph node status

ER status

PR status

Her2 status

β1 integrin expression

Rac1 expression

ER:estrogen receptor, PR:progesterone receptor, HER-2:human epidermal growth factor.
receptor 2, IMPC:invasive micropapillary carcinoma.
*
P values were calculated by Spearman’s Rank-Correlation test.
www.impactjournals.com/oncotarget
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pathologic diagnosis of IMPC, particularly regarding
the required proportion of micropapillary clusters in a
nonhomogeneous tumor. In this study, we selected tumors
consisting of at least 50% IMPC component. Based on
previous studies, we hypothesized that tumor cell polarity
reversal is a critical factor facilitating metastasis. The
integrins constitute a family of polarity-related proteins, and
their upregulation in breast cancer cells has been reported
[27], although conflicting results have also been described
[28]. We chose to study the expression of β1 integrin and
Rac1 in breast cancer cell lines and IMPC and correlated
our findings with the clinicopathologic features of patients.
To our knowledge, this is the first study to investigate the
role of β1 integrin and Rac1 expression in IMPC.
We showed that when β1 integrin expression
was blocked in the MCF-10A cell line by siRNA-β1
integrin, the expression of Rac1 was also significantly
downregulated. In contrast, when Rac1 expression
was blocked in the same cell line by siRNA-Rac1, no

significant decrease in β1 integrin expression was found.
The results confirm that, at least in the MCF-10A cell line,
β1 integrin positively regulates Rac1 expression, but not
the reverse, and indicate that Rac1 is in a downstream
position to β1 integrin in the chain of molecular processes
that maintain epithelial cell polarity.
Using 3D culture, we demonstrated that the polarity
of MCF-10A clusters became disordered after treatment
with siRNA-β1 integrin; the cell clusters were transformed
from normal clusters with a hollow growth pattern to
irregular cell clusters, as reported previously by others [19,
20]. Weaver et al. [17] reported that treatment of breast
cancer cells with inhibitory β1 integrin antibody leads
to a striking morphologic and functional reversion to a
normal phenotype. We confirmed these results in our study,
in which treatment with the β1 integrin inhibitor AIIB2
partially abrogated the polarity reversal seen in IMPC
clusters. These results indicate that upregulation of β1
integrin causes polarity reversal of IMPC cells, followed by

Figure 5: Kaplan-Meier curves showing the prognostic value of β1 integrin, Rac1, and (reversal of) MUC-1 expression
in IMPC. (A) High β1 integrin expression was correlated with shorter disease-free survival (DFS) (P = 0.017). (B) High Rac1expression
was correlated with shorter DFS (P = 0.027). (C) MUC-1 reversed pattern was correlated with shorter DFS (P = 0.004). (D) The DFS of
patients with high β1 integrin and Rac1 expression was shorter than that of patients with high expression of only one of these markers (both
high vs β1 integrin high, P = 0.029; both high vs Rac1 high, P = 0.019; and both high vs both low, P = 0.15).
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Table 8: Univariate and multivariate cox regression analysis for disease-free survival of breast IMPC patients
HR

Univariable
95% CI

P value

HR

0.835

0.395–1.769

0.639

–

–

–

1.856

1.036–3.327

0.038

2.091

1.166–3.749

0.013

1.043

0.517–2.105

0.907

–

–

–

9.080

1.227–67.192

0.031

3.521

0.459–27.032

0.226

Negative vs Positive

0.922

0.436–1.950

0.832

–

–

–

PR status
Negative vs Positive

0.701

0.333–1.475

0.349

–

_

–

0.980

0.396–2.426

0.965

–

–

–

Low vs High

7.806

1.060–57.479

0.044

2.913

0.379–22.379

0.304

Rac1 expression
Low vs High
MUC-1 expression

4.446

1.054–18.754

0.042

3.005

0.666–13.553

0.152

11.658

1.543–88.061

0.017

8.005

1.025–62.521

0.047

Variables
Age (years)
≤52 vs ﹥52
Tumor size (T stage)
T1 vs T2 vs T3–T4

Multivariable
95% CI

P value

Histological grade
I vs II vs III
Lymph node status
No metastasis vs
metastasis
ER status

Her2 status
Negative vs Positive
β1 integrin expression

Non-reversed pattern
vs Reversed pattern

ER: estrogen receptor, PR: progesterone receptor, HER-2: human epidermal growth factor receptor 2, IMPC: invasive
micropapillary carcinoma, HR: hazard ratio, CI: confidence interval.
formation of tumor cell clusters as a result of upregulation
of Rac1. This could explain how morula-like clusters of
IMPC are formed and could support our previous findings
that IMPC tumor cells divorce from primary tumor and then
invade and metastasize through tumor cell clusters [12].
Our immunohistochemical analysis revealed that β1
integrin and Rac1 expression was higher in IMPC than in
paraneoplastic benign breast tissue and IDC-NST. IMPC
patients with high expression of both β1 integrin and Rac1
had a significantly higher incidence of LNM than patients
with low expression of both markers or with high expression
of only one marker. In patients with IMPC that showed weak
expression of β1 integrin and/or Rac1, the incidence of LNM
was significantly greater than in patients with no expression.
A similar trend was observed in patients with IDC-NST. A
study in patients with IDC-NST showed that increased Rac1
expression was associated with partial reversed cell polarity
and LNM, which supports the idea that IDC-NST with partial
reversed cell polarity may be part of the IMPC spectrum [8,
29]. Univariate analysis showed that β1 integrin and Rac1
overexpression was associated with tumor cell polarity
reversal, presence of LNM, and decreased DFS in IMPC
www.impactjournals.com/oncotarget

patients. Multivariate analysis indicated that polarity reversal
was an independent predictor for poor DFS in IMPC patients.
These results suggest that upregulated β1 integrin may promote
LNM of IMPC through formation of tumor clusters with
polarity reversal. Perhaps this proposed model could be applied
to other metastasis-prone tumors with IMPC growth patterns,
including tumors of the lungs, ovaries, and colon [1–3].
Of note, patients with IMPC with high expression of
both β1 integrin and Rac1 had a worse DFS than patients
with high expression of either β1 integrin or Rac1. One
explanation for this result is that tumor cell polarity reversal
might require Rac1 to be activated by β1 integrin. Both β1
integrin and Rac1 could be involved in multiple molecular
pathways, and activation of Rac1 by other unknown factors
might lead to unrelated biologic events. This might explain
why high expression of Rac1 alone had virtually no impact
on DFS and why high expression of β1 integrin alone had
minimal impact (Figure 5D). In addition, the prognostic
difference between high expression of both markers and
low expression of both markers did not reach statistical
significance. However, the number of IMPC patients
included in the clinical assessment was small, and it is
4349
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possible that low expression of both β1 integrin and Rac1
represents another abnormality unrelated to polarity reversal.
Investigations using greater numbers of patients are required
to validate these findings.
In conclusion, this study indicates that that high
metastatic potential of breast IMPC is associated with polarity
reversal of tumor cell clusters. β1 integrin positively regulates
Rac1, an important factor involved in polarity reversal in
IMPC. Overexpression of β1 integrin and the associated
upregulation of Rac1 are associated with cancer cell polarity
reversal, presence of LNM, and poor DFS, and polarity
reversal is an independent predictor of poor prognosis of
breast IMPC patients. Additional studies are warranted to
validate these findings and to further explore the mechanisms
involved in tumor growth and metastasis of breast IMPC.

Tianjin Medical University Institutional Review Board,
and informed consent was obtained from all participants.

Cell culture
MCF-7 and MDA-MB-231 cell lines were grown in
DMEM high glucose supplemented with 10% fetal bovine
serum and 1% penicillin-streptomycin (P/S) solution at
37°C in a 5% CO2 incubator. The MCF-10A cell line was
grown in DMEM/F12 supplemented with 5% horse serum,
10 μg/mL of insulin, 20 ng/mL of epidermal growth factor,
0.5 μg/mL of hydrocortisone, 1% NEAA, and 1% P/S
solution at 37°C in a 5% CO2 incubator.
In breast cancer primary culture, after removal of
adipose tissue, tumor tissue was treated as previously
described [31]. Cells cultured in flask were then digested
and centrifuged. Collagen gel was prepared on ice for
3D cell culture. The cells were counted and embedded
in collagen gel with a cell density of 1.5 × 105/mL. The
collagen gel was then planted in a 24-well plate. After
incubation at 37°C for 1 hour, complete medium was
added and changed in 3-day intervals. After incubation for
3 to 7 days, spheroids of various sizes were harvested. For
the inhibitor assessment, AIIB2 (7.5 µg/mL) was added on
the day of planting, and the medium was replaced with a
new one containing fresh inhibitor every 3 days. Control
cultures were treated with ordinary medium only.

MATERIALS AND METHODS
Antibodies used include anti-β1 integrin (ab52971,
Abcam), anti-Rac1 (ab33186, Abcam), anti-E-cad
(ab1416, Abcam), and anti-MUC-1 (ab109185, Abcam).
Other reagents included β1 integrin inhibitor AIIB2
(Developmental Studies Hybridoma Bank, United States),
type I collagenase (Solarbio, China), collagen gel (Nitta
Gelatin, Japan), culture media (Gibco), and Lipofectamine
2000 and TRIzol (Invitrogen). siRNAs were synthesized
by GenePharma, China, and the sequences were as
follows: siRNA-β1 integrin: forward, 5′-GUU UAA UGU
CUG GUG CUU TT-3′; reverse, 5′-AAG CAC CAG ACA
UUA AAC TT-3′; siRNA-Rac1: forward, 5′-UAA AGA
CAC GAU CGA GAA AUU-3′; reverse, 5′-UUU CUC
GAU CGU GUC UUU AUU-3′; and siRNA-ctrl: forward,
5′-UUC UCC GAA CGU GUC ACG UTT-3′; reverse,
5′-ACGUGACACGUUCGGAGAATT-3′.

siRNA transfection
Cells were treated with siRNA and Lipofectamine
2000. After 6 hours of incubation, transfection medium
was replaced with complete culture medium for 48 hours.
To verify the siRNA efficacy, cells were lysed and β1
integrin and Rac1 expression was analyzed by real-time
polymerase chain reaction (PCR) and Western blot.

Breast cancer tissue samples

Real-time PCR

Formalin-fixed, paraffin-embedded tissue blocks
from 102 patients with breast IMPC collected from 2007
to 2008 were retrieved from the archive of the Department
of Breast Cancer Pathology and Research Laboratory,
Tianjin Medical University Cancer Hospital, Tianjin,
China. All cases had an IMPC component constituting
>50% of the tumor volume. Paraneoplastic benign
breast tissue was available in 48 blocks. In addition, 100
random cases of IDC-NST were retrieved during the same
period as the control group. The diagnosis was confirmed
independently by two pathologists using World Health
Organization (WHO) criteria [30]. None of the patients
received preoperative radiation or chemotherapy. Patients
were followed for 1 to 100 months, with a median followup time of 63 months. Fresh tumor tissue samples were
obtained from five IMPC and five IDC-NST patients
who underwent surgical resection from November 2015
to May 2016. The research protocol was approved by the
www.impactjournals.com/oncotarget

TRIzol reagent was used to isolate RNA from
cultured cells. cDNA was synthesized by SuperScript
III reverse transcriptase (Invitrogen) using random
primers. PCR reactions were performed using QuantiTect
SYBR Green RT-PCR Kit (Qiagen), according to the
manufacturer’s instructions. The sequences of the
semiquantitative reverse transcriptase PCR primers were
as follows: β1 integrin: forward 5′-CAT CTG CGA GTG
TGG TGT CT-3′, reverse 5′-GGG GTA ATT TGT CCC
GAC TT-3′; Rac1: forward 5′-AGC TTT TGC GGA
GAT TTT GA-3′, reverse 5′-CCC GTG ACA CTT TCA
TTC CT-3′; and GAPDH: forward 5′-CGG AGT CAA
CGG ATT TGG TCG TAT-3′, reverse 5′-AGC CTT CTC
CAT GGT GGT GAA GAC-3′. Initial denaturation was
at 94°C for 2 minutes, followed by 30 cycles of 94°C for
20 seconds and 60° for 30 seconds.
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Western blot

β1 integrin immunoreactivity was scored based
on the percentage of positive tumor cells: 0: ≤ 10%; 1+:
11%–25%; 2+: 26%–50%; and 3+: > 50% [14]. Cases were
assigned to high expression (2+ or 3+) or low expression (0
or 1+) groups, per the previously described method [34]. In
Rac1 evaluation, cases were divided into three groups (0:
0%; 1+: 1%–33%; and 2+: ≥ 34%) and further classified
as high expression (2+) or low expression (0 or 1+) [35].
MUC-1 reversed pattern was defined as the presence of
complete linear reactivity on the outer surface of tumor cell
clusters facing stroma (ie, polarity reversal) [36].

Three-dimensional cultured collagen gel was
digested by type I collagenase and centrifuged before
protein extraction. Total protein extracts from 3D cell
cultures were prepared as described previously [24]. The
protein concentration of each lysate was measured using
the BCA method (Beyotime, China). Twenty micrograms
of protein from each sample were separated by 10% SDSpolyacrylamide gel electrophoresis and transferred to
PVDF membranes (Millipore, Billerica, MA) for 2 hours.
The membranes were blocked with 5% skim milk for 1
hour. After overnight incubation with primary antibody
β1 integrin (1:5000) and Rac1 (1:5000), membranes
were incubated with secondary antibodies for 1 hour, and
proteins were detected using the LiCor Odyssey Infrared
Imaging System. Anti-β-actin antibodies were used as
internal control.

Statistical analysis
Statistical analysis was carried out using SPSS 19.0.
Differences among groups were analyzed using the MannWhitney U test. Correlations between two variables were
evaluated using Spearman’s rank correlation analysis.
Survival curves for DFS and OS were constructed using
the Kaplan-Meier method, and the differences between
two groups were assessed using the log-rank test. Cox
proportional hazards models were used to perform
univariate and multivariable analysis. A two-tailed
P < 0.05 was considered statistically significant.

Immunofluorescence analysis
Primary tumor cells in 3D culture were fixed
with 4% paraformaldehyde for 20 minutes and washed
three times with phosphate-buffered saline (PBS); then
0.25% Triton X-100 (PBS prepared) was added for 20
minutes. The collagen gel was blocked with 3% BSA for
40 minutes. The cells were then washed with PBS and
incubated with primary antibodies E-cad (1:50) or MUC-1
(1:200) overnight at 4°C in a dark wet chamber, followed
by incubation with secondary antibodies (ZF-0316/ZF0312; Zhongshan Golden Bridge, China) for 2 hours at
room temperature. After washing with PBS, the nuclei
were counterstained with DAPI (blue). Immunofluorescent
images were captured by the Olympus IX51 (Olympus,
Tokyo, Japan) confocal microscope. Experiments were
repeated a minimum of three times.
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